Description: he company has a strong global presence with over 78% of its sales from overseas
arkets. They produce a wide array of quality, generic products that are preferred by
ealth professionals and patients worldwide. While Ranbaxy’s strength lies in quality
enerics, it is slowly moving toward New Chemical Entities (NCE) and Novel Drug
Delivery Systems (NDDS) in supporting its
aspires to break into new m
a
gain access to advanced technologies.
long-term growth focus. The company
arkets as a research-based pharmaceutical entity. It has
ctively pursued strategic alliances and acquisitions to develop areas of expertise and
